Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28665306 | 1.00 | OPRD1 (0.48) | OPRD1KMT2APREPF2ACE | |
| SCHEMBL29444020 | 0.97 | OPRD1 (0.49) | OPRD1KMT2APREPF2ACE | |
| SCHEMBL21462327 | 0.97 | OPRD1 (0.49) | OPRD1KMT2APREPF2ACE | |
| SCHEMBL31258873 | 0.97 | OPRD1 (0.49) | OPRD1KMT2APREPF2ACE | |
| SCHEMBL30034009 | 0.94 | OPRD1 (0.47) | OPRD1KMT2APREPF2ACE | |
| SCHEMBL28679703 | 0.87 | OPRD1 (0.47) | OPRD1KMT2APREPF2DPP7 | |
| SCHEMBL28559438 | 0.87 | F2 (0.46) | OPRD1KMT2APREPF2ACE | |
| SCHEMBL29565875 | 0.87 | KMT2A (0.54) | OPRD1KMT2AF2ACEALDH1A1 | |
| SCHEMBL4575275 | 0.84 | ALDH1A1 (0.53) | KMT2APREPF2FKBP1AALDH1A1 | |
| SCHEMBL119867 | 0.84 | ALDH1A1 (0.53) | KMT2APREPF2FKBP1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119539-A1 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119539-A1 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | NR3C1, SSB, SERPINA6 | OPRD1 4271/4885KMT2A 2035/4885PREP 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.